304 related articles for article (PubMed ID: 26087898)
1. Exome-level comparison of primary well-differentiated neuroendocrine tumors and their cell lines.
Boora GK; Kanwar R; Kulkarni AA; Pleticha J; Ames M; Schroth G; Beutler AS; Banck MS
Cancer Genet; 2015; 208(7-8):374-81. PubMed ID: 26087898
[TBL] [Abstract][Full Text] [Related]
2. Whole-exome characterization of pancreatic neuroendocrine tumor cell lines BON-1 and QGP-1.
Vandamme T; Peeters M; Dogan F; Pauwels P; Van Assche E; Beyens M; Mortier G; Vandeweyer G; de Herder W; Van Camp G; Hofland LJ; Op de Beeck K
J Mol Endocrinol; 2015 Apr; 54(2):137-47. PubMed ID: 25612765
[TBL] [Abstract][Full Text] [Related]
3. Site-Specific Genomic Alterations in a Well-Differentiated Pancreatic Neuroendocrine Tumor With High-Grade Progression.
Martin DR; LaBauve E; Pomo JM; Chiu VK; Hanson JA; Gullapalli RR
Pancreas; 2018 Apr; 47(4):502-510. PubMed ID: 29521944
[TBL] [Abstract][Full Text] [Related]
4. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
Park C; Ha SY; Kim ST; Kim HC; Heo JS; Park YS; Lauwers G; Lee J; Kim KM
Oncotarget; 2016 Jan; 7(4):4024-35. PubMed ID: 26684240
[TBL] [Abstract][Full Text] [Related]
5. Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.
Simbolo M; Mafficini A; Sikora KO; Fassan M; Barbi S; Corbo V; Mastracci L; Rusev B; Grillo F; Vicentini C; Ferrara R; Pilotto S; Davini F; Pelosi G; Lawlor RT; Chilosi M; Tortora G; Bria E; Fontanini G; Volante M; Scarpa A
J Pathol; 2017 Mar; 241(4):488-500. PubMed ID: 27873319
[TBL] [Abstract][Full Text] [Related]
6. Hotspot DAXX, PTCH2 and CYFIP2 mutations in pancreatic neuroendocrine neoplasms.
Vandamme T; Beyens M; Boons G; Schepers A; Kamp K; Biermann K; Pauwels P; De Herder WW; Hofland LJ; Peeters M; Van Camp G; Op de Beeck K
Endocr Relat Cancer; 2019 Jan; 26(1):1-12. PubMed ID: 30021865
[TBL] [Abstract][Full Text] [Related]
7. Integrated Genomic and Clinicopathologic Approach Distinguishes Pancreatic Grade 3 Neuroendocrine Tumor From Neuroendocrine Carcinoma and Identifies a Subset With Molecular Overlap.
Umetsu SE; Kakar S; Basturk O; Kim GE; Chatterjee D; Wen KW; Hale G; Shafizadeh N; Cho SJ; Whitman J; Gill RM; Jones KD; Navale P; Bergsland E; Klimstra D; Joseph NM
Mod Pathol; 2023 Mar; 36(3):100065. PubMed ID: 36788102
[TBL] [Abstract][Full Text] [Related]
8. Loss of Chromatin-Remodeling Proteins and/or CDKN2A Associates With Metastasis of Pancreatic Neuroendocrine Tumors and Reduced Patient Survival Times.
Roy S; LaFramboise WA; Liu TC; Cao D; Luvison A; Miller C; Lyons MA; O'Sullivan RJ; Zureikat AH; Hogg ME; Tsung A; Lee KK; Bahary N; Brand RE; Chennat JS; Fasanella KE; McGrath K; Nikiforova MN; Papachristou GI; Slivka A; Zeh HJ; Singhi AD
Gastroenterology; 2018 Jun; 154(8):2060-2063.e8. PubMed ID: 29486199
[TBL] [Abstract][Full Text] [Related]
9. Genomic characterization of a well-differentiated grade 3 pancreatic neuroendocrine tumor.
Williamson LM; Steel M; Grewal JK; Thibodeau ML; Zhao EY; Loree JM; Yang KC; Gorski SM; Mungall AJ; Mungall KL; Moore RA; Marra MA; Laskin J; Renouf DJ; Schaeffer DF; Jones SJM
Cold Spring Harb Mol Case Stud; 2019 Jun; 5(3):. PubMed ID: 31160355
[TBL] [Abstract][Full Text] [Related]
10. Establishment and characterization of the third non-functional human pancreatic neuroendocrine tumor cell line.
Lou X; Ye Z; Xu X; Jiang M; Lu R; Jing D; Zhang W; Gao H; Wang F; Zhang Y; Chen X; Qin Y; Zhuo Q; Yu X; Ji S
Hum Cell; 2022 Jul; 35(4):1248-1261. PubMed ID: 35394261
[TBL] [Abstract][Full Text] [Related]
11. Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms.
Young G; Wang K; He J; Otto G; Hawryluk M; Zwirco Z; Brennan T; Nahas M; Donahue A; Yelensky R; Lipson D; Sheehan CE; Boguniewicz AB; Stephens PJ; Miller VA; Ross JS
Cancer Cytopathol; 2013 Dec; 121(12):688-94. PubMed ID: 23893923
[TBL] [Abstract][Full Text] [Related]
12. Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4/cdk6.
Tang LH; Contractor T; Clausen R; Klimstra DS; Du YC; Allen PJ; Brennan MF; Levine AJ; Harris CR
Clin Cancer Res; 2012 Sep; 18(17):4612-20. PubMed ID: 22761470
[TBL] [Abstract][Full Text] [Related]
13. Genomic landscape of pancreatic neuroendocrine tumors.
Gebauer N; Schmidt-Werthern C; Bernard V; Feller AC; Keck T; Begum N; Rades D; Lehnert H; Brabant G; Thorns C
World J Gastroenterol; 2014 Dec; 20(46):17498-506. PubMed ID: 25516664
[TBL] [Abstract][Full Text] [Related]
14. Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice?
Luchini C; Lawlor RT; Bersani S; Vicentini C; Paolino G; Mattiolo P; Pea A; Cingarlini S; Milella M; Scarpa A
Curr Oncol Rep; 2021 Jul; 23(9):106. PubMed ID: 34269919
[TBL] [Abstract][Full Text] [Related]
15. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.
Marinoni I; Kurrer AS; Vassella E; Dettmer M; Rudolph T; Banz V; Hunger F; Pasquinelli S; Speel EJ; Perren A
Gastroenterology; 2014 Feb; 146(2):453-60.e5. PubMed ID: 24148618
[TBL] [Abstract][Full Text] [Related]
16. Exome Sequencing and CNV Analysis on Chromosome 18 in Small Intestinal Neuroendocrine Tumors: Ruling Out a Suspect?
Delgado Verdugo A; Crona J; Maharjan R; Hellman P; Westin G; Björklund P
Horm Metab Res; 2015 Jun; 47(6):452-5. PubMed ID: 25354328
[TBL] [Abstract][Full Text] [Related]
17. The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines.
Hofving T; Arvidsson Y; Almobarak B; Inge L; Pfragner R; Persson M; Stenman G; Kristiansson E; Johanson V; Nilsson O
Endocr Relat Cancer; 2018 Mar; 25(3):367-380. PubMed ID: 29444910
[TBL] [Abstract][Full Text] [Related]
18. Next generation exome sequencing of pancreatic neuroendocrine tumor cell lines BON-1 and QGP-1 reveals different lineages.
Vandamme T; Beyens M; Peeters M; Van Camp G; de Beeck KO
Cancer Genet; 2015 Oct; 208(10):523. PubMed ID: 26341699
[No Abstract] [Full Text] [Related]
19. Aberrant Menin expression is an early event in pancreatic neuroendocrine tumorigenesis.
Hackeng WM; Brosens LA; Poruk KE; Noë M; Hosoda W; Poling JS; Rizzo A; Campbell-Thompson M; Atkinson MA; Konukiewitz B; Klöppel G; Heaphy CM; Meeker AK; Wood LD
Hum Pathol; 2016 Oct; 56():93-100. PubMed ID: 27342911
[TBL] [Abstract][Full Text] [Related]
20. A vicious partnership between AKT and PHLDA3 to facilitate neuroendocrine tumors.
Takikawa M; Ohki R
Cancer Sci; 2017 Jun; 108(6):1101-1108. PubMed ID: 28295876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]